Skip to content

Press Releases

Apr 02, 2019
Esperion to Present at the Needham & Company 18th Annual Healthcare Conference
ANN ARBOR, Mich., April 02, 2019 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR), the Lipid Management Company focused on developing and commercializing complementary, cost-effective, convenient, once-daily, oral therapies for the treatment of patients with elevated low density lipoprotein cholesterol
Apr 01, 2019
Esperion Announces Publication in The Journal of the American Heart Association of Bempedoic Acid Study 3 Results
 –  Study 3 Demonstrated Bempedoic Acid Significantly Lowered LDL-Cholesterol and Reduced hsCRP in Patients Considered Statin Intolerant – –  Over 24-Weeks, Bempedoic Acid Was Observed to be Safe, Well-Tolerated, and the Muscle-Related Adverse Event Rate Did Not Differ from Placebo – –  Bempedoic
Mar 18, 2019
Esperion Announces Late-Breaking Presentation of Final Results of Bempedoic Acid Pivotal Phase 3 Study 2 at the American College of Cardiology 2019 Scientific Sessions
–Study 2 Demonstrated Bempedoic Acid Significantly Lowered LDL-Cholesterol and Reduced hsCRP– –Over 52-Weeks, Bempedoic Acid was Observed to be Safe, Well-Tolerated, and Adverse Event Profile was Similar to that of Placebo– –Bempedoic Acid is an Oral, Once-daily ATP Citrate Lyase (ACL) Inhibitor
Mar 13, 2019
Esperion Announces Publication of Bempedoic Acid Study 1 Results in The New England Journal of Medicine
–  Study 1 Demonstrated Bempedoic Acid Significantly Lowered LDL-Cholesterol and Reduced hsCRP – –  Over 52-Weeks, Bempedoic Acid was Observed to be Safe, Well-Tolerated, and Did Not Lead to Higher Overall Adverse Events Compared With Placebo – –  Bempedoic Acid is an Oral, Once-daily ATP Citrate
Mar 04, 2019
Esperion to Participate in Upcoming Investor Conferences
ANN ARBOR, Mich., March 04, 2019 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR), the Lipid Management Company focused on developing and commercializing complementary, cost-effective, convenient, once-daily, oral therapies for the treatment of patients with elevated low density lipoprotein cholesterol
Mar 04, 2019
Esperion Announces Presentation of Bempedoic Acid Pivotal Phase 3 Study 2 Results in a Late-Breaking Clinical Trial Session at the American College of Cardiology 2019 Scientific Sessions
ANN ARBOR, Mich., March 04, 2019 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today announced that the results from Study 2 (1002-047, also known as CLEAR Wisdom, a pivotal Phase 3 study) of bempedoic acid will be presented in a late-breaking clinical trial session at the American College of
Feb 28, 2019
Esperion Provides Bempedoic Acid Franchise Development Program Updates; Reports Fourth Quarter and Full Year 2018 Financial Results
ANN ARBOR, Mich., Feb. 28, 2019 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR), the Lipid Management Company focused on developing and commercializing complementary, cost-effective, convenient, once-daily, oral therapies for the treatment of patients with elevated low density lipoprotein cholesterol
Feb 28, 2019
Esperion Announces Submissions of Two NDAs and Official Completion of Two MAA Validations for Both Bempedoic Acid and the Bempedoic Acid / Ezetimibe Combination Tablet
ANN ARBOR, Mich., Feb. 28, 2019 (GLOBE NEWSWIRE) -- Esperion (Nasdaq: ESPR) today announced that the company has successfully completed important and key global marketing applications including the submission of two New Drug Applications (NDAs) for bempedoic acid and the bempedoic acid / ezetimibe
Feb 22, 2019
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
ANN ARBOR, Mich., Feb. 22, 2019 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR), the Lipid Management Company focused on developing and commercializing convenient, complementary, cost-effective, once-daily, oral therapies for the treatment of patients with elevated low density lipoprotein cholesterol
Jan 04, 2019
Esperion Announces Agreement with Daiichi Sankyo Europe (DSE) to Commercialize Bempedoic Acid in Europe
–     Esperion to Receive $300 Million in Upfront and Near-term Milestones    – –     Up to $900 Million in Total Milestones     – –     Substantial Tiered Royalties     – –     Esperion Partnering with a European CV Sales Organization Exceeding 1000 and One of the Most Successful European-based
Jan 02, 2019
Esperion to Present at the 37th Annual J.P. Morgan Healthcare Conference
ANN ARBOR, Michigan , Jan. 02, 2019 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR), the Lipid Management Company focused on developing and commercializing complementary, convenient, cost-effective, once-daily, oral therapies for the treatment of patients with elevated low density lipoprotein